Table 3.
Studies regarding masseter muscle injections.
| Author, Year of Publication | Study Group Size | Wet/Dry Needling (Injected Substance) |
Navigation Method or Support System |
Needle Penetration Spot(s) | Amount of Injected Substance (per Muscle) |
Number of Treatment Sessions |
|---|---|---|---|---|---|---|
| Al-Wayli, 2017 [21] | 25 | BTX | manual palpation; deposition spots located regularly in the lower part of the muscle | 3 sites | 20 IU | 1 |
| Ananthan, 2019 [22] | 25 | LA (2% lidocaine) |
digital palpation | MTPs | ns | 1 |
| Chaurand, 2020 [23] | 22 | BTX | digital palpation | 2 sites | 30 IU | 1 |
| Chaurand, 2017 [24] | 11 | BTX | manual palpation; one spot near mandibular angle and one near zygomatic arch | 2 sites | 20 IU | 1 |
| Ernberg, 2011 [25] | 21 | BTX | EMG; 15 mm deep | 3 sites | 50 IU | 2 |
| Ghavimi, 2019 [26] | 61 | BTX | manual palpation; deposition spots located regularly along the long axis of the muscle; 10 mm deep |
3 sites | 50 IU | 1 |
| Guarda-Nardini, 2012 [27] | 15 | BTX | manual palpation; 2 cm skin surface over most prominent area of the muscle after clenching | minimum 5 sites in reverse pyramid pattern | ns | 1 |
| Hosgor, 2020 [28] | 44 | BTX | manual palpation | 3 sites | 150 IU | 1 |
| Ivask,2016 [29] | 20 | BTX | manual palpation; most painful spot | 5 sites | ns | 1 |
| Kang, 2018 [30] | 24 | LA (1,5 or 5 mg morphine sulfate) |
manual palpation; most painful spot | 1 site | 0.3 mL | 1 |
| Kang, 2018 [30] | 11 | LA (2% lidocaine) |
manual palpation; most painful spot | 1 site | 0.3 mL | 1 |
| Kim, 2016 [30] | 21 | BTX | manual palpation | 3 sites | 150 IU | 1 |
| Meral, 2019 [31] | 25 | BTX | Ns | 6 sites | 24 IU | 1 |
| Nitecka-Buchta, 2019 [32] | 29 | PRP | manual palpation; 5–10 mm deep |
3 MTPs near the origin, under zygomatic arch | 1.5 mL | 1 |
| Nitecka-Buchta, 2018 [9] | 18 | collagen | manual palpation; 10–15 mm deep |
MTPs | 2 mL | 2 |
| Nitecka-Buchta, 2018 [9] | 15 | LA (2% lidocaine) |
manual palpation; 10–15 mm deep |
MTPs | 2 mL | 2 |
| Ozden, 2018 [33] | 20 | DDN | manual palpation and analogue algometer; 10 mm deep |
MTPs | - | 3 |
| Ozden, 2018 [33] | 20 | SDN | manual palpation and analogue algometer; 5 mm deep |
MTPs | - | 3 |
| Patel, 2017 [34] | 20 | BTX | EMG and monopolar electrode injection needle | ns | 50 IU | 1 |
| Pihut, 2016 [35] | 42 | BTX | manual palpation, area of the greatest cross-section surface of both masseter bellies | ns | 21 IU | 1 |
| Pons, 2018 [36] | 6 | BTX | manual palpation | 3 sites | 30 IU | 1 |
| Sipahi Calis, 2019 [13] | 9 | BTX | EMG | ns | 30 IU | 1 |
| Taskesen, 2020 [37] | 15 | DDN | manual palpation | MTPs | - | 2 |
| Taskesen, 2020 [37] | 15 | LA (2% lidocaine) |
manual palpation | MTPs | 0.2 mL | 2 |
| Tesch, 2019 [38] | 5 | DDN | manual palpation | MTPs | - | 3 |
| Uemoto, 2013 [39] | 7 | LA (2% lidocaine) |
digital palpation; 10–20 mm deep |
MTPs | 0.25 mL | 4 |
| Uemoto, 2013 [39] | 7 | DDN | digital palpation | MTPs | - | 4 |
| Villa, 2018 [40] | 28 | BTX | Ns | 3 sites | 50 IU | 1 |
| Yilmaz, 2020 [41] | 26 | BTX | manual palpation | MTPs | 10 U/MTP | 1 |
| Yilmaz, 2020 [41] | 27 | LA (3% mepivacaine) |
manual palpation | MTPs | 0.5 mL/MTP | 1 |
| Yilmaz, 2020 [41] | 29 | PRP | manual palpation | MTPs | 0.5 mL/MTP | 1 |
| Yurttutan, 2019 [42] | 48 | BTX | manual palpation; deposition spots located regularly across the muscle mass | 5 sites | 30 IU | 1 |